{"id":47709,"date":"2025-11-13T22:35:32","date_gmt":"2025-11-13T14:35:32","guid":{"rendered":"https:\/\/flcube.com\/?p=47709"},"modified":"2025-11-13T22:35:33","modified_gmt":"2025-11-13T14:35:33","slug":"eirgenix-secures-152-m-licensing-deal-for-eg1206a-breast%e2%80%91cancer-biosimilar-from-sandoz","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=47709","title":{"rendered":"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz"},"content":{"rendered":"\n<p><strong>EirGenix Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/6589:TPE\">TPE: 6589<\/a>)<\/strong> announced a second, worldwide exclusive licensing agreement with Sandoz AG (<a href=\"https:\/\/www.google.com\/finance\/quote\/SDZ:SWX\">SWX: SDZ<\/a>) to commercialize its independently developed pertuzumab biosimilar, <strong>EG1206A<\/strong>\u2014Roche\u2019s Perjeta counterpart\u2014across all territories outside of Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, Japan, and the entire ASEAN\u2011EMEA region.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Financial Terms<\/strong><\/li>\n\n\n\n<li>Up to <strong>USD\u202f152\u202fmillion<\/strong> in upfront and milestone payments.<\/li>\n\n\n\n<li>Profit\u2011share mechanics post\u2011launch, plus sales\u2011incentive tiers tied to market performance.<\/li>\n\n\n\n<li><strong>Scope and Responsibilities<\/strong><\/li>\n\n\n\n<li>EirGenix leads product development, manufacturing, and supply chain management.<\/li>\n\n\n\n<li>Sandoz provides marketing, distribution, and commercial expertise in the licensed territories.<\/li>\n\n\n\n<li><strong>Territorial Cadence<\/strong><\/li>\n\n\n\n<li>All countries <strong>except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-amp-regulatory-context\">Scientific &amp; Regulatory Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Milestone<\/strong><\/li>\n\n\n\n<li>EG1206A has completed its pharmacokinetic (PK) study and received <strong>positive feedback<\/strong> from the <strong>U.S. FDA<\/strong> and <strong>EMA<\/strong>.<\/li>\n\n\n\n<li>The regulatory outcome confirms eligibility for an <strong>abbreviated development pathway<\/strong>, enabling waiver of Phase\u202f3 comparative efficacy trials.<\/li>\n\n\n\n<li><strong>Strategic Positioning<\/strong><\/li>\n\n\n\n<li>EG1206A represents the third biosimilar in EirGenix\u2019s portfolio, following the prior AGX licensing of <strong>EG12014 (trastuzumab)<\/strong>.<\/li>\n\n\n\n<li>The deal positions EirGenix as a growing player within the lucrative <strong>breast\u2011cancer biosimilar market<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-investor-impact\">Investor Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cash\u2011Flow Advantage<\/strong> \u2013 Immediate up\u2011front and milestone income potentially boosting the 2025 earnings guide.<\/li>\n\n\n\n<li><strong>Revenue\u2011Sharing Structure<\/strong> \u2013 Long\u2011term upside as EG1206A captures market share across >\u202f50 high\u2011growth markets.<\/li>\n\n\n\n<li><strong>Operational Focus<\/strong> \u2013 By handling R&amp;D and manufacturing, EirGenix retains control over supply\u2011chain efficiencies.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>The comments made herein are forward\u2011looking and are subject to risks and uncertainties. Material adverse changes may cause actual results to differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":47718,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[43,1882,747,886,4460],"class_list":["post-47709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-biosimilars","tag-eirgenix","tag-sandoz","tag-swx-sdz","tag-tpe-6589"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX: SDZ) to commercialize its independently developed pertuzumab biosimilar, EG1206A\u2014Roche\u2019s Perjeta counterpart\u2014across all territories outside of Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, Japan, and the entire ASEAN\u2011EMEA region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=47709\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz\" \/>\n<meta property=\"og:description\" content=\"EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX: SDZ) to commercialize its independently developed pertuzumab biosimilar, EG1206A\u2014Roche\u2019s Perjeta counterpart\u2014across all territories outside of Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, Japan, and the entire ASEAN\u2011EMEA region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=47709\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-13T14:35:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-13T14:35:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz\",\"datePublished\":\"2025-11-13T14:35:32+00:00\",\"dateModified\":\"2025-11-13T14:35:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709\"},\"wordCount\":293,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1308.webp\",\"keywords\":[\"Biosimilars\",\"EirGenix\",\"Sandoz\",\"SWX: SDZ\",\"TPE: 6589\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47709#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=47709\",\"name\":\"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1308.webp\",\"datePublished\":\"2025-11-13T14:35:32+00:00\",\"dateModified\":\"2025-11-13T14:35:33+00:00\",\"description\":\"EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX: SDZ) to commercialize its independently developed pertuzumab biosimilar, EG1206A\u2014Roche\u2019s Perjeta counterpart\u2014across all territories outside of Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, Japan, and the entire ASEAN\u2011EMEA region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47709\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1308.webp\",\"width\":1080,\"height\":608,\"caption\":\"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47709#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz - Insight, China&#039;s Pharmaceutical Industry","description":"EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX: SDZ) to commercialize its independently developed pertuzumab biosimilar, EG1206A\u2014Roche\u2019s Perjeta counterpart\u2014across all territories outside of Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, Japan, and the entire ASEAN\u2011EMEA region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=47709","og_locale":"en_US","og_type":"article","og_title":"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz","og_description":"EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX: SDZ) to commercialize its independently developed pertuzumab biosimilar, EG1206A\u2014Roche\u2019s Perjeta counterpart\u2014across all territories outside of Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, Japan, and the entire ASEAN\u2011EMEA region.","og_url":"https:\/\/flcube.com\/?p=47709","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-13T14:35:32+00:00","article_modified_time":"2025-11-13T14:35:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=47709#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=47709"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz","datePublished":"2025-11-13T14:35:32+00:00","dateModified":"2025-11-13T14:35:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=47709"},"wordCount":293,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=47709#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1308.webp","keywords":["Biosimilars","EirGenix","Sandoz","SWX: SDZ","TPE: 6589"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=47709#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=47709","url":"https:\/\/flcube.com\/?p=47709","name":"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=47709#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=47709#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1308.webp","datePublished":"2025-11-13T14:35:32+00:00","dateModified":"2025-11-13T14:35:33+00:00","description":"EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX: SDZ) to commercialize its independently developed pertuzumab biosimilar, EG1206A\u2014Roche\u2019s Perjeta counterpart\u2014across all territories outside of Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, Japan, and the entire ASEAN\u2011EMEA region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=47709#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=47709"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=47709#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1308.webp","width":1080,"height":608,"caption":"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=47709#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"EirGenix Secures $152\u202fM Licensing Deal for EG1206A Breast\u2011Cancer Biosimilar from Sandoz"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47709"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47709\/revisions"}],"predecessor-version":[{"id":47720,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47709\/revisions\/47720"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/47718"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}